Abacavir/Dolutegravir/Lamivudi
Brand name: Triumeq
Rank #78 of 500 drugs by total cost
$238.1M
Total Cost
61,147
Total Claims
$238.1M
Total Cost
1,743
Prescribers
$3,894
Cost per Claim
2,720
Beneficiaries
64,330
30-Day Fills
$137K
Avg Cost/Provider
35
Avg Claims/Provider
About Abacavir/Dolutegravir/Lamivudi
Abacavir/Dolutegravir/Lamivudi (sold as Triumeq) was prescribed 61,147 times by 1,743 Medicare Part D providers in 2023, costing the program $238.1M. At $3,894 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 75 | Metoprolol Succinate (Metoprolol Succinate) | $256.3M | 12,847,535 |
| 76 | Dolutegravir Sodium (Tivicay) | $251.7M | 102,995 |
| 77 | Abemaciclib (Verzenio) | $242.2M | 16,125 |
| 78 | Abacavir/Dolutegravir/Lamivudi (Triumeq) | $238.1M | 61,147 |
| 79 | Riociguat (Adempas) | $236.6M | 17,620 |
| 80 | Elviteg/Cob/Emtri/Tenof Alafen (Genvoya) | $236.5M | 56,626 |
| 81 | Emtricitabine/Tenofov Alafenam (Descovy) | $222.4M | 94,580 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology